Buprenorphine Group Treatment For Opioid Addiction. Ken Saffier , MD, Natasha Pinto, MD And Patients CCRMC/HC Noon Conference February 18, 2010. Disclosures.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Buprenorphine Group Treatment For Opioid Addiction
Ken Saffier, MD, Natasha Pinto, MD
CCRMC/HC Noon Conference
February 18, 2010
Drs. Pinto and Saffier have no financial interest or other relationship with the manufacturer of any commercial product discussed in this presentation.
At the end of this presentation, participants will be able to:
Number of mentions
. Oxycodone and hydrocodone both registered substantial increases in emergency department mentions in the last 5 years
Source: SAMHSA, Drug Abuse Warning Network.
Past Year Dependent/Abusers, Ages 12 or Older (in Thousands)
Source: SAMHSA, 2002 National Survey on Drug Use and Health.
Issues of Concern
Percent of 12th Graders Reporting
Nonmedical Use of OxyContin and Vicodin
in the Past Year Remained High
No year-to-year differences are statistically significant.
Intrinsic mu Activity: Full Agonist (Methadone), Partial Agonist (Buprenorphine), Antagonist (Naloxone)
Log Dose of Opioid
Zubieta et al., 2000
Gooseflesh (cold turkey)
Restless sleep, then
N/V, diarrhea, cramps
Remaining in treatment (nr)
4 Subjects in Control Group Died
Treatment duration (days)
Substance Abuse and Mental Health Administration
Center for Substance Abuse Treatment
Treatment Improvement Protocol (TIP) Series
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction # 40
National Clearinghouse for Alcohol and Drug Information
(800) 729 – 6686 or (301) 468 – 2600
(discounted for residents)